Professional Records
Lawyers & Attorneys
Xing Dai - Lawyer
View pageLicenses:
Dist. of Columbia - Active 1995
Xing Dai Phones & Addresses
-
Plano, TX
-
Richmond, TX
-
Houston, TX
-
51 Monroe St, New York, NY 10002 (212) 566-8568
-
51 Monroe St #17, New York, NY 10002 (212) 566-8568
Ranks
Licence:
Dist. of Columbia - Active
Date:
1995
Resumes
Resumes
Xing Dai
View pagePublications
Us Patents
Spiro-Imidazolone Derivatives As Glucagon Receptor Antagonists
View pageUS Patent:
20110178007, Jul 21, 2011
Filed:
Sep 30, 2009
Appl. No.:
13/121725
Inventors:
Andrew Stamford - Chatham Township NJ, US
Michael W Miller - Scotch Plains NJ, US
Duane Eugene Demong - Somerset NJ, US
William J Greenlee - Teaneck NJ, US
Joseph A Kozlowski - Princeton NJ, US
Brian J Lavey - New Providence NJ, US
Michael K.C. Wong - Somerset NJ, US
Wensheng Yu - Edison NJ, US
Xing Dai - Cranford NJ, US
De-Yi Yang - Morris Plains NJ, US
Guowei Zhou - Somerset NJ, US
Michael W Miller - Scotch Plains NJ, US
Duane Eugene Demong - Somerset NJ, US
William J Greenlee - Teaneck NJ, US
Joseph A Kozlowski - Princeton NJ, US
Brian J Lavey - New Providence NJ, US
Michael K.C. Wong - Somerset NJ, US
Wensheng Yu - Edison NJ, US
Xing Dai - Cranford NJ, US
De-Yi Yang - Morris Plains NJ, US
Guowei Zhou - Somerset NJ, US
International Classification:
A61K 31/4184
C07D 235/02
C07D 403/12
C07D 491/107
A61K 31/4188
C07D 401/14
A61K 31/4439
C07F 7/10
A61K 31/695
C07D 405/14
C07D 405/04
A61K 31/4709
A61K 38/28
A61K 38/16
A61K 38/22
A61K 31/7034
A61K 31/70
A61K 31/7048
A61P 3/10
C07D 235/02
C07D 403/12
C07D 491/107
A61K 31/4188
C07D 401/14
A61K 31/4439
C07F 7/10
A61K 31/695
C07D 405/14
C07D 405/04
A61K 31/4709
A61K 38/28
A61K 38/16
A61K 38/22
A61K 31/7034
A61K 31/70
A61K 31/7048
A61P 3/10
US Classification:
514 59, 5483007, 548251, 514387, 514381, 546 15, 514278, 548253, 548110, 514 63, 514 69, 514 97, 514 35, 514 23
Abstract:
The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R, R, Z, L, and Lare selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
Iminothiadiazepane Dioxide Compounds As Bace Inhibitors, Compositions, And Their Use
View pageUS Patent:
20170037056, Feb 9, 2017
Filed:
Dec 16, 2014
Appl. No.:
15/104257
Inventors:
Xing DAI - Kenilworth NJ, US
Jared N. CUMMING - Kenilworth NJ, US
Jack D. SCOTT - Kenilworth NJ, US
Hong LIU - Kenilworth NJ, US
Anandan PALANI - Kenilworth NJ, US
- Rahway NJ, US
Jared N. CUMMING - Kenilworth NJ, US
Jack D. SCOTT - Kenilworth NJ, US
Hong LIU - Kenilworth NJ, US
Anandan PALANI - Kenilworth NJ, US
- Rahway NJ, US
Assignee:
MERCK SHARP & DOHME CORP. - Rahway NJ
International Classification:
C07D 513/04
C07D 471/04
C07D 285/36
C07D 417/12
C07D 471/04
C07D 285/36
C07D 417/12
Abstract:
In its many embodiments, the present invention provides certain iminothiadiazepane dioxide compounds, including compounds Formula (I):or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R, R, R, R, R, R, ring A, R, m, -L-, and Rare as defined herein. The novel compounds of the invention are useful as BACE inhibitors and may be useful for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
Compounds Inhibiting Leucine-Rich Repeat Kinase Enzyme Activity
View pageUS Patent:
20160289207, Oct 6, 2016
Filed:
Nov 10, 2014
Appl. No.:
15/035255
Inventors:
- Rahway NJ, US
Michael Miller - Scotch Plains NJ, US
Hong Liu - Hillsborough NJ, US
Xing Dai - Cranford NJ, US
Thomas Greshock - Collegeville PA, US
Andrew Stamford - Chatham NJ, US
Ravi Nargund - East Brunswick NJ, US
Michael Miller - Scotch Plains NJ, US
Hong Liu - Hillsborough NJ, US
Xing Dai - Cranford NJ, US
Thomas Greshock - Collegeville PA, US
Andrew Stamford - Chatham NJ, US
Ravi Nargund - East Brunswick NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 401/04
C07D 401/14
C07D 401/14
Abstract:
The present invention is directed to substituted indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Compounds Inhibiting Leucine-Rich Repeat Kinase Enzyme Activity
View pageUS Patent:
20160200722, Jul 14, 2016
Filed:
Aug 18, 2014
Appl. No.:
14/912761
Inventors:
Duane DEMONG - Kenilworth NJ, US
Thomas J. GRESHOCK - West Point PA, US
Ronald K. CHANG - West Point PA, US
Xing DAI - Kenilworth NJ, US
Hong LIU - Kenilworth NJ, US
John A. MCCAULEY - West Point PA, US
Wei LI - Kenilworth PA, US
Kallol BASU - Kenilworth PA, US
Jack D. SCOTT - Kenilworth PA, US
Michael MILLER - Kenilworth PA, US
- Rahway NJ, US
Thomas J. GRESHOCK - West Point PA, US
Ronald K. CHANG - West Point PA, US
Xing DAI - Kenilworth NJ, US
Hong LIU - Kenilworth NJ, US
John A. MCCAULEY - West Point PA, US
Wei LI - Kenilworth PA, US
Kallol BASU - Kenilworth PA, US
Jack D. SCOTT - Kenilworth PA, US
Michael MILLER - Kenilworth PA, US
- Rahway NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 471/04
C07D 498/04
C07D 519/00
C07D 498/04
C07D 519/00
Abstract:
The present invention is directed to azaindazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Heterocyclic Compounds And Methods Of Use Thereof For The Treatment Of Hepatitis C
View pageUS Patent:
20160143895, May 26, 2016
Filed:
Jun 19, 2014
Appl. No.:
14/897966
Inventors:
Shuwen He - Kenilworth NJ, US
Zhong Lai - Kenilworth NJ, US
Xing Dai - Cranford NJ, US
Dong Xiao - Kenilworth NJ, US
Clare London - Chatham NJ, US
Nicolas Zorn - Durmenach, FR
Ravi Nargund - Kenilworth NJ, US
Anandan Palani - Kenilworth NJ, US
Casey C. McComas - Phoenixville PA, US
Peng Li - Shanghai, CN
Xuanjia Peng - Shanghai, CN
Richard Soll - Cambridge MA, US
Zhong Lai - Kenilworth NJ, US
Xing Dai - Cranford NJ, US
Dong Xiao - Kenilworth NJ, US
Clare London - Chatham NJ, US
Nicolas Zorn - Durmenach, FR
Ravi Nargund - Kenilworth NJ, US
Anandan Palani - Kenilworth NJ, US
Casey C. McComas - Phoenixville PA, US
Peng Li - Shanghai, CN
Xuanjia Peng - Shanghai, CN
Richard Soll - Cambridge MA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/454
A61K 45/06
A61K 31/5377
A61K 31/423
A61K 31/496
A61K 31/404
C07D 405/04
A61K 31/4525
C07D 405/14
C07D 471/04
A61K 31/4545
C07D 498/04
C07D 417/14
C07D 495/04
C07D 413/14
A61K 45/06
A61K 31/5377
A61K 31/423
A61K 31/496
A61K 31/404
C07D 405/04
A61K 31/4525
C07D 405/14
C07D 471/04
A61K 31/4545
C07D 498/04
C07D 417/14
C07D 495/04
C07D 413/14
Abstract:
The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.(I)
Substituted Benzofuran Compounds And Methods Of Use Thereof For The Treatment Of Viral Diseases
View pageUS Patent:
20160136172, May 19, 2016
Filed:
Jun 19, 2014
Appl. No.:
14/898768
Inventors:
Xing DAI - Rahway NJ, US
Hong LIU - Rahway NJ, US
Anandan PALANI - Rahway NJ, US
Shuwin HE - Rahway NJ, US
Ravi NARGUND - Rahway NJ, US
Dong XIAO - Rahway NJ, US
Nicolas ZORN - Fanwood NJ, US
Qun DANG - Rahway NJ, US
Casey C. MCCOMAS - Phoenixville PA, US
Xuanjia PENG - Shnghai, CN
Peng LI - Shanghai, CN
Richard SOLL - Shanghai, CN
Hong LIU - Rahway NJ, US
Anandan PALANI - Rahway NJ, US
Shuwin HE - Rahway NJ, US
Ravi NARGUND - Rahway NJ, US
Dong XIAO - Rahway NJ, US
Nicolas ZORN - Fanwood NJ, US
Qun DANG - Rahway NJ, US
Casey C. MCCOMAS - Phoenixville PA, US
Xuanjia PENG - Shnghai, CN
Peng LI - Shanghai, CN
Richard SOLL - Shanghai, CN
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/5365
C07D 471/04
A61K 31/519
C07D 405/04
A61K 45/06
C07D 475/02
A61K 31/437
A61K 31/4725
A61K 31/53
C07D 405/14
C07D 498/04
A61K 31/517
C07D 471/04
A61K 31/519
C07D 405/04
A61K 45/06
C07D 475/02
A61K 31/437
A61K 31/4725
A61K 31/53
C07D 405/14
C07D 498/04
A61K 31/517
Abstract:
The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
Substituted Benzofuran Compounds And Methods Of Use Thereof For The Treatment Of Viral Diseases
View pageUS Patent:
20160130259, May 12, 2016
Filed:
Jun 19, 2014
Appl. No.:
14/898250
Inventors:
- Rahway NJ, US
Xing Dai - Cranford NJ, US
Anandan Palani - Bridgewater NJ, US
Shuwen He - Fanwood NJ, US
Ravi Nargund - East Brunswick NJ, US
Dong Xiao - Warren NJ, US
Qun Dang - Westfield NJ, US
Xuanjia Peng - Shanghai, CN
Peng Li - Shanghai, CN
Xing Dai - Cranford NJ, US
Anandan Palani - Bridgewater NJ, US
Shuwen He - Fanwood NJ, US
Ravi Nargund - East Brunswick NJ, US
Dong Xiao - Warren NJ, US
Qun Dang - Westfield NJ, US
Xuanjia Peng - Shanghai, CN
Peng Li - Shanghai, CN
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 405/14
C07D 491/048
C07D 498/04
C07D 471/04
C07D 471/14
A61K 31/4985
A61K 31/4439
A61K 31/444
A61K 31/501
A61K 31/497
A61K 31/506
C07D 413/14
A61K 45/06
C07D 491/048
C07D 498/04
C07D 471/04
C07D 471/14
A61K 31/4985
A61K 31/4439
A61K 31/444
A61K 31/501
A61K 31/497
A61K 31/506
C07D 413/14
A61K 45/06
Abstract:
The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
Compounds Inhibiting Leucine-Rich Repeat Kinase Enzyme Activity
View pageUS Patent:
20160009681, Jan 14, 2016
Filed:
Feb 27, 2014
Appl. No.:
14/772525
Inventors:
Michael MILLER - Kenilworth NJ, US
Kallol BASU - Kenilworth NJ, US
Duane MONG - Kenilworth NJ, US
Jack SCOTT - Kenilworth NJ, US
Hong LIU - Kenilworth NJ, US
Xing DAI - Kenilworth NJ, US
Andrew STAMFORD - Rahway NJ, US
Marc POIRIER - Kenilworth NJ, US
Paul TEMPEST - , US
- Rahway NJ, US
Kallol BASU - Kenilworth NJ, US
Duane MONG - Kenilworth NJ, US
Jack SCOTT - Kenilworth NJ, US
Hong LIU - Kenilworth NJ, US
Xing DAI - Kenilworth NJ, US
Andrew STAMFORD - Rahway NJ, US
Marc POIRIER - Kenilworth NJ, US
Paul TEMPEST - , US
- Rahway NJ, US
International Classification:
C07D 401/04
C07D 498/08
C07D 401/14
C07D 495/08
C07D 498/04
C07D 487/04
C07D 413/14
C07D 405/14
C07D 417/14
C07D 498/08
C07D 401/14
C07D 495/08
C07D 498/04
C07D 487/04
C07D 413/14
C07D 405/14
C07D 417/14
Abstract:
The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.